Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g. , hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Despite the availability of an effective vaccine, there are still 400 million people worldwide who are chronically infected with the hepatitis B and D viruses (HBV and HDV), and more work still needs to be done in all of the key areas of managing the disease. In Hepatitis B and D Protocols, leading investigators and clinicians have joined forces to create a broad-ranging collection of cutting-edge techniques for the study of HBV and HDV infections and for the development of therapies to treat them. In this second of two volumes, Immunology, Model Systems, and Clinical Studies, the authors focus on protocols for the study of host immune responses to infection, in vitro and in vivo models of infection, and the development of antivirals. Each fully tested protocol is described in step-by-step detail by an established expert in the field and includes a background introduction outlining the principle underlying the technique, equipment and reagent lists, and tips on troubleshooting and avoiding known pitfalls. An accompanying first volume, Detection, Genotypes, and Characterization, contains user-friendly protocols for the identification and quantification of viral markers, the detection and impact of viral variants, and the study of the viral life cycle.
Taken together, Hepatitis B and D Protocols, Volume 1: Detection, Genotypes, and Characterization and Volume 2: Immunology, Model Systems, and Clinical Studies offer both new and experienced investigators an encyclopedic collection of powerful tools for studying HBV and HDV infections, as well as an essential resource for finding new therapies to treat chronically infected patients.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Ammareal, Morangis, Frankreich
Hardcover. Zustand: Très bon. Ancien livre de bibliothèque. Légères traces d'usure sur la couverture. Salissures sur la tranche. Edition 2004. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Slight signs of wear on the cover. Stains on the edge. Edition 2004. Ammareal gives back up to 15% of this item's net price to charity organizations. Bestandsnummer des Verkäufers E-417-726
Anzahl: 1 verfügbar
Anbieter: SMASS Sellers, IRVING, TX, USA
Zustand: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed. Bestandsnummer des Verkäufers ASNNN-11271
Anbieter: Basi6 International, Irving, TX, USA
Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Bestandsnummer des Verkäufers ABEOCT25-173932
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Bestandsnummer des Verkäufers ABBB-11271
Anbieter: SMASS Sellers, IRVING, TX, USA
Zustand: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed. Bestandsnummer des Verkäufers ASNT3-11271
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. pp. 600 1st Edition. Bestandsnummer des Verkäufers 26289308
Anzahl: 1 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. pp. 600. Bestandsnummer des Verkäufers 7591363
Anzahl: 1 verfügbar
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. pp. 600. Bestandsnummer des Verkäufers 18289302
Anzahl: 4 verfügbar
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In. Bestandsnummer des Verkäufers ria9781588291080_new
Anzahl: Mehr als 20 verfügbar
Anbieter: moluna, Greven, Deutschland
Gebunden. Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infe. Bestandsnummer des Verkäufers 4221405
Anzahl: Mehr als 20 verfügbar